amiodarone + diltiazem + esmolol

Amiodarone, diltiazem, and esmolol represent a combination of three distinct cardiovascular medications, each with potent effects on cardiac function. Amiodarone is a Class III antiarrhythmic that primarily prolongs the cardiac action potential by blocking potassium channels, but also exhibits properties of Class I (sodium channel blockade), Class II (beta-adrenergic blockade), and Class IV (calcium channel blockade) antiarrhythmics. Diltiazem is a non-dihydropyridine calcium channel blocker (Class IV antiarrhythmic) that inhibits calcium ion influx into cardiac and vascular smooth muscle, leading to vasodilation, decreased heart rate, and reduced contractility. Esmolol is a cardioselective beta-1 adrenergic blocker (Class II antiarrhythmic) with a rapid onset and short duration of action, which decreases heart rate, contractility, and conduction by antagonizing beta-1 receptors. While each drug is individually approved for various cardiac arrhythmias, hypertension, and angina, their combined use would be highly complex and carries a significant risk of severe cardiodepressant effects, including profound bradycardia, heart block, and hypotension, due to their overlapping mechanisms of action. Such a combination is not typically formulated as a single product and would only be considered with extreme caution and close monitoring in specific, acute clinical scenarios.

Other names

amiodarone, diltiazem, esmolol-Seoul National University Hospital-atrial fibrillation-atrial flutteramiodaronediltiazemesmolol